SPARC: The Standardised Prostate-specific Membrane Antigen PET-CT Analysis and Reporting Consensus Open access: https://t.co/eRV0qqREB6 @Uroweb @EUplatinum Bringing together all the PSMA guidelines into one modern consensus. Please use a template when reporting PSMA PET/CT !

Seems to be a lot of CNS lymphoma around these days. Do joint us to learn about its optimal management .

Two comprehensive reviews on new bispecific antibodies in #lymphoma made pretty and online @Haematologica #lymsm @AdrianMinson @nancybartlettMD

This is finally out! More to come from the FOLL12 trial by fil #flsm #lymsm

"While the UK is a global leader in clinical research, many solutions to today’s complex health challenges - such as reducing the lives lost to the biggest killers - will come from working together across borders." 🫱🏽‍🫲🏼🌏 📝 In her latest blog, our CEO Professor @LucyChappell2

Timely tour de force review on Mantle Cell Lymphoma: Optimal Treatment With Bruton Tyrosine Kinase–Targeted Approaches | @JCO_ASCO @tobyeyre82

#VIOLET Study of Terbium-161 (Tb-161) Beta/Auger therapy @ASCO #ASCO25 First prospective trial of Terbium-161 in any tumour type 🟣 30 patient trial in prostate cancer. No dose limiting toxicities at highest level of radioactivity (7.4 GBq) 🟣 Very few side effects: 1 grade 3

Abstract deadline approaching May31 for submissions to #PILM2025. Come join us to discuss hot topics in lymphoma and myeloma in beautiful Menton France 12-13 September 2025 @AnneSegolene @c_thieblemont @IreneBuvat @AndreaGallamini3 https://t.co/dyNcIWQAoy https://t.co/aJPSbhd9to

We are seeking a clinical trial co-ordinator who wants to make a true impact... at @PeterMacCC . you’ll lead the coordination of our @pros_tic clinical trials, building on more than a decade of global leadership in cutting-edge research. Why Join Us? ⦿ Global Recognition: We

For the first time ever the UK has more female than male doctors, with 164 440 women (50.04%) and 164 195 men (49.96%) registered with a licence to practise, show data from the GMC https://t.co/lbKXDbZ7YR

@DrMHofman @pros_tic @Prof_IanD @ANZUPtrials @SNM_MI @Uroweb @EANM_NucMed @TheranosticsAus @anzsnm1969 @ProfKHerrmann We would like to inform you that your post has been published on @Oncodaily. Thank you for sharing! https://t.co/500FsqcXLR

⚕️ @WomenInLymphoma Steering Committee members, advocates, sponsors and supporters from all over the world🌍networking and sharing connections, initiatives and experience at #ASH24 #lymsm #lymphoma @ASH_hematology

Number 3 #LeonardList #ASH24 top #lymphoma abstract 235 – Lewis – Ibrutinib-R v chemo-R in pts w/untreated MCL (Enrich) – How would newer BTKi do? BTKi upfront similar to B-R. We know BTKi effective 2ndline p chemo-R, chemo role after upfront BTKi unknown! https://t.co/9fnwz2tfta

A great reminder that cutting-edge large axial field-of-view "#TotalBodyPET scanners not only allow entirely new research avenues but also benefit patients immediately! #PET #KingsCollegeLondon #GSTT #NPIP #ImperialCollegeLondon

Patients at @GSTTnhs will benefit from a full-body scanner that will enable more effective diagnosis of patients with serious diseases. It will feed findings into the National PET Imaging Platform, building a bank of data from patients to support development of new medicines.

Watch Dr @sohaibnazir, Clinical Senior Lecturer and Consultant Cardiologist at #Kingsimaging, explain how our new Total Body PET scanner will benefit healthcare research and improve patient outcomes🏥⬇️ #MedTech #Healthcare

We see the elevation of glofitamab from 3rd line+ DLBCL to 2nd line+ combined with R-GemOx with STARGLO. Will it reach 1st line DLBCL? We await with interest results from the fully recruited SKYGLO study (Pola-R-CHP vs glofit-Pola-R-CHP).

👉Catch up with #IndolentLymphoma Session 3 @AnneSegolene @ClementineSar 🔗Recording https://t.co/jLeCtuH7Ov #lymphoma #lymsm With thanks to @GileadSciences #IFLI @EliLillyandCo @lymphomaOz

Pr Catherine Thieblemont @LysaLymphoma @WomenInLymphoma @lymphoma_uk meeting - MTV & ENsites on PET and LDH used routinely to select for CART in France. Time for MTV in routine practice in UK with new international benchmark https://t.co/SgosdPXhhD @KCLGSTTpet @KingsImaging

Mike Bennett Memorial lecture from Pr Catherine Thieblemont @LysaLymphoma @WomenInLymphoma at UK lymphoma research group annual meeting @lymphoma_uk reports exciting times ahead as unprecedented anti tumor activity in RR DLBCL of CART and bispecifics moves into 1st line